These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Influence of sustained viral response on the regression of fibrosis and portal hypertension in cirrhotic HCV patients treated with antiviral triple therapy. Puente Á; Cabezas J; López Arias MJ; Fortea JI; Arias MT; Estébanez Á; Casafont F; Fábrega E; Crespo J Rev Esp Enferm Dig; 2017 Jan; 109(1):17-25. PubMed ID: 27990835 [TBL] [Abstract][Full Text] [Related]
23. Endothelial dysfunction in the regulation of cirrhosis and portal hypertension. Iwakiri Y Liver Int; 2012 Feb; 32(2):199-213. PubMed ID: 21745318 [TBL] [Abstract][Full Text] [Related]
25. Portal pressure and liver stiffness measurements in the prediction of fibrosis regression after sustained virological response in recurrent hepatitis C. Mauro E; Crespo G; Montironi C; Londoño MC; Hernández-Gea V; Ruiz P; Sastre L; Lombardo J; Mariño Z; Díaz A; Colmenero J; Rimola A; Garcia-Pagán JC; Brunet M; Forns X; Navasa M Hepatology; 2018 May; 67(5):1683-1694. PubMed ID: 28960366 [TBL] [Abstract][Full Text] [Related]
26. Pathophysiology of portal hypertension in HCV-related cirrhosis. Putative role of assessment of portal pressure gradient in Peginterferon-treated patients. Ratti L; Pozzi M; Bosch J Dig Liver Dis; 2005 Nov; 37(11):886-93. PubMed ID: 16172033 [TBL] [Abstract][Full Text] [Related]
27. Predictive value of liver and spleen stiffness measurement based on two-dimensional shear wave elastography for the portal vein pressure in patients with compensatory viral cirrhosis. Wang P; Hu X; Xie F PeerJ; 2023; 11():e15956. PubMed ID: 37727690 [TBL] [Abstract][Full Text] [Related]
29. The hyperdynamic circulation in cirrhosis: an overview. Blendis L; Wong F Pharmacol Ther; 2001 Mar; 89(3):221-31. PubMed ID: 11516477 [TBL] [Abstract][Full Text] [Related]
30. Liver fibrosis emulation: Impact of the vascular fibrotic alterations on hemodynamics. Torres Rojas AM; Lorente S Comput Biol Med; 2023 Nov; 166():107563. PubMed ID: 37852110 [TBL] [Abstract][Full Text] [Related]
31. Current concepts on the role of nitric oxide in portal hypertension. Hu LS; George J; Wang JH World J Gastroenterol; 2013 Mar; 19(11):1707-17. PubMed ID: 23555159 [TBL] [Abstract][Full Text] [Related]
32. Persistence of Clinically Significant Portal Hypertension After Eradication of Hepatitis C Virus in Patients With Advanced Cirrhosis. Díez C; Berenguer J; Ibañez-Samaniego L; Llop E; Pérez-Latorre L; Catalina MV; Hontañón V; Jiménez-Sousa MA; Aldámiz-Echevarría T; Martínez J; Calleja JL; Albillos A; Bellón JM; Resino S; González-García J; Bañares R Clin Infect Dis; 2020 Dec; 71(10):2726-2729. PubMed ID: 32386053 [TBL] [Abstract][Full Text] [Related]
33. Infection as a Trigger for Portal Hypertension. Steib CJ; Schewe J; Gerbes AL Dig Dis; 2015; 33(4):570-6. PubMed ID: 26159275 [TBL] [Abstract][Full Text] [Related]
34. Treatment of portal hypertension with NCX-1000, a liver-specific NO donor. A review of its current status. Fiorucci S; Antonelli E; Tocchetti P; Morelli A Cardiovasc Drug Rev; 2004; 22(2):135-46. PubMed ID: 15179450 [TBL] [Abstract][Full Text] [Related]
35. The beneficial effects of curcumin in cirrhotic rats with portal hypertension. Hsu SJ; Lee JY; Lin TY; Hsieh YH; Huang HC; Lee FY; Lin HC; Hou MC; Lee SD Biosci Rep; 2017 Dec; 37(6):. PubMed ID: 29162665 [TBL] [Abstract][Full Text] [Related]
37. The usefulness of non-invasive liver stiffness measurements in predicting clinically significant portal hypertension in cirrhotic patients: Korean data. Hong WK; Kim MY; Baik SK; Shin SY; Kim JM; Kang YS; Lim YL; Kim YJ; Cho YZ; Hwang HW; Lee JH; Chae MH; Kim HA; Kang HW; Kwon SO Clin Mol Hepatol; 2013 Dec; 19(4):370-5. PubMed ID: 24459641 [TBL] [Abstract][Full Text] [Related]
38. New cellular and molecular targets for the treatment of portal hypertension. Gracia-Sancho J; Maeso-Díaz R; Fernández-Iglesias A; Navarro-Zornoza M; Bosch J Hepatol Int; 2015 Apr; 9(2):183-91. PubMed ID: 25788198 [TBL] [Abstract][Full Text] [Related]
39. Hemodynamic alterations in cirrhosis and portal hypertension. Kim MY; Baik SK; Lee SS Korean J Hepatol; 2010 Dec; 16(4):347-52. PubMed ID: 21415576 [TBL] [Abstract][Full Text] [Related]
40. Novelties in the pathophysiology and management of portal hypertension: new treatments on the horizon. Kang SH; Kim MY; Baik SK Hepatol Int; 2018 Feb; 12(Suppl 1):112-121. PubMed ID: 28698986 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]